Patrick Daly

DocwireNews

Therapy with short-term, fixed-dose isoquercetin exhibited no off-target bleeding and induced positive reductions in several biomarkers for thromboinflammation in patients with <a href="https://www.docwirenews.com/page/sickle-cell-disease">sickle cell disease</a> (SCD), according to a randomized controlled trial published in Blood Advances.The data &ldquo;confirm the utility of a relatively inexpensive and safe oral flavonoid with demonstrable efficacy in reducing several thromboinflammatory biomarkers in SCD,&rdquo; wrote the study&rsquo;s authors, led by Maria Lizarralde-Iragorri, PhD, from the National Heart Lung and Blood Institute at the National Institutes of Health in Bethesda, Maryland.Between November 2019 and July 2022, researchers enrolled 46 adults with a mean age of 40 &plusmn; 11 years with steady-state SCD variants. The cohort was 56% female and 75% were receiving hydroxyurea treatment. After randomization, 23 patients received isoquercetin and 23 received placebo.Treatment Reduces Inflammation in Sickle Cell Disease Isoquercertin was well tolerated, and the authors stated that the 21 adverse events (AEs) and 14 serious AEs were not related to treatment. After treatment, the mean change from baseline in plasma soluble P-selectin (the primary outcome) was not significantly different between the groups at 0.10 &plusmn; 6.53 with <a href="https://pubchem.ncbi.nlm.nih.gov/compound/Isoquercetin" target="_blank" rel="noopener">isoquercetin</a> versus 0.74 &plusmn; 4.54 with placebo (P=.64); however, isoquercetin did significantly reduce or inhibit the following:<ul>
<li>Whole-blood coagulation (P=.03)</li>
<li>Collagen-induced platelet aggregation (P=.03)</li>
<li>Inducible mononuclear cell tissue factor gene expression (P=.003)</li>
<li>Plasma protein disulfide isomerase reductase activity (P=.02)</li>
</ul>Considering these data together, &ldquo;findings suggest that trials of higher dose [isoquercetin] for more extended treatment durations are required for patients with SCD,&rdquo; Dr. Lizarralde-Iragorri and colleagues wrote.ReferenceLizarralde-Iragorri MA, Gopalan BP, Merriweather B, et al. Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial. Blood Adv. 2024;8(1):172-182. doi:10.1182/bloodadvances.2023011542hemetoRelated: <a href="https://www.docwirenews.com/post/exa-cel-approved-in-saudi-arabia-for-sickle-cell-disease-beta-thalassemia">Exa-Cel Approved in Saudi Arabia for Sickle Cell Disease, Beta Thalassemia</a>

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Could Isoquercetin Solve Thromboinflammation in Sickle Cell Disease?

Sickle Cell Disease

Therapy with isoquercetin induced positive reductions in several biomarkers for thromboinflammation in sickle cell disease.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe